true FY 0001792941

 2022-03-31

 2023-03-24

 us-gaap: RelatedPartyMember

 us-gaap: RelatedPartyMember

 srt: ScenarioPreviouslyReportedMember

 srt: RevisionOfPriorPeriodReclassificationAdjustmentMember

 srt: ScenarioPreviouslyReportedMember

 srt: RevisionOfPriorPeriodReclassificationAdjustmentMember

 GNVR:PaycheckProtectionProgramMember

 2020-04-09

 2021-03-31
 2021-03-31

 2021-03-31
 2021-03-31

 GNVR:AgromedLLCMember

 2020-08-22
 2020-08-22

 GNVR:AgromedLLCMember
 us-gaap: PatentsMember

 GNVR:NoteholderBMember

 GNVR:NoteholderAMember

 GNVR:NoteholderAMember

 GNVR:NoteholderBMember

 GNVR:NoteholderCMember

 GNVR:NoteholderCMember

 GNVR:NoteholderDMember

 GNVR:NoteholderDMember

 GNVR:NoteholderEMember

 GNVR:NoteholderEMember

 GNVR:NoteholderFMember

 GNVR:NoteholderFMember

 GNVR:NoteholderGMember

 GNVR:NoteholderGMember

 GNVR:NoteholderHMember

 GNVR:NoteholderIMember

 GNVR:NoteholderHMember

 GNVR:NoteholderFMember
 srt: MinimumMember

 GNVR:NoteholderFMember
 srt: MaximumMember

 2022-08-10

 2022-08-02
 2022-08-10

 2022-04-21
 2022-04-21

 2022-04-21

 2022-06-30

 GNVR:TransferAndExchangeAgreementMember

 2022-07-01
 2022-07-31

 GNVR:TransferAndExchangeAgreementMember

 2022-07-31

 GNVR:NexionContractorMember

 2022-09-08
 2022-09-08

 GNVR:BusinessAdvisoryServicesMember

 GNVR:BusinessAdvisoryServicesMember

 us-gaap: InvestorMember

 2022-02-18
 2022-02-18

 GNVR:DirectorThreeMember

 2022-03-08
 2022-03-08

 srt: DirectorMember

 2022-03-08
 2022-03-08

 2022-04-01
 2022-04-30

 2022-09-13
 2022-09-13

 srt: MinimumMember

 srt: MaximumMember

 2022-02-28

 2022-02-28

 2022-05-12
 2022-05-12

 2022-05-12

 GNVR:SubscriptionAgreementsMember

 2022-07-01
 2022-07-31

 GNVR:DecemberTwentyTwentyOneStockPurchaseAgreementMember

 2022-07-01
 2022-07-31

 us-gaap: WarrantMember

 us-gaap: WarrantMember

 us-gaap: WarrantMember

 2021-01-03
 2021-01-04

 us-gaap: WarrantMember

 2021-01-04
 2021-01-04

 2021-12-19
 2021-12-20

 us-gaap: InvestorMember

 2020-07-24
 2020-07-24

 GNVR:OneConsultingAgreementsMember

 GNVR:TwoConsultingAgreementsMember

 GNVR:TwoAdvisorsMember

 2021-09-01
 2021-09-30

 us-gaap: ResearchAndDevelopmentArrangementMember

 us-gaap: ResearchAndDevelopmentArrangementMember

 GNVR:ThreeFoundersMember

 2020-12-01

 GNVR:ThreeFoundersMember

 2022-08-16

 GNVR:ChiefScientificOfficerAndChairmanMember

 2022-08-16

 GNVR:ChiefResearchOfficerAndDirectorMember

 2022-08-16

 GNVR:CEOAndBoardMember

 GNVR:CEOAndBoardMember

 2019-01-01

 2022-09-01

 2021-09-01
 2021-09-30

 us-gaap: RelatedPartyMember

 us-gaap: RelatedPartyMember

 GNVR:RobertBubeckMember

 2021-09-30

 GNVR:OldGenvorMember

 GNVR:OldGenvorMember

 GNVR:OldGenvorMember

 GNVR:OldGenvorMember

 GNVR:JaynesInvestmentLLCMember

 GNVR:ACTHoldingsLLCMember

 GNVR:LASBFamilyTrustMember

 GNVR:JesseMichaelJaynesMember

 GNVR:BradleyWhiteMember

 GNVR:PJAdvisoryGroupMember

 U.S.
SECURITIES AND EXCHANGE COMMISSION

 Washington,
D.C. 20549

 FORM
 10-K/A

 Mark
One

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For
the fiscal year ended: September 30, 2022

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For
the transition period from _________ to _________

 Commission
File No. 333-234815

 GENVOR
 INCORPORATED

 (Exact
 name of registrant as specified in its charter)

 Nevada

 83-2054746

 (State
 or Other Jurisdiction of

 Incorporation
 or Organization)

 (IRS
 Employer

 Identification
 Number)

 13155
Noel Road, Suite 900,

 Dallas,
 Texas 75240

 (214) 427-1921

 (Address
and telephone number of principal executive offices)

 Securities
registered pursuant to Section 12(b) of the Act:

 Title
 of each class

 Trading
 Symbol(s)

 Name
 of each exchange on which registered

 Not
 applicable.

 Securities
registered under Section 12(g) of the Act:

 Not
applicable.

 (Title
of class)

by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No

by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes No

by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant
was required to submit and post such files). Yes No

by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller
reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

 Large
 accelerated filer

 Accelerated
 filer

 Non-accelerated
 filer

 Smaller
 reporting company

 Emerging
 growth company

 If securities are registered pursuant to
Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the
correction of an error to previously issued financial statements.

 Indicate by check mark whether any of those
error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's
executive officers during the relevant recovery period pursuant to §240.10D-1(b).

by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report.

 On
March 31, 2022, the last business day of the registrant's most recently completed second fiscal quarter, the aggregate market value
of the registrant's common stock held by non-affiliates of the registrant had an undetermined value as the registrant's common
stock was no t trading on any exchange, nor was it quoted for trading on the OTC Link ATS or any other over-the-counter market or alternative
trading system.

 The
number of the registrant's shares of common stock outstanding was 18,122,821 as of March 24, 2023.

 EXPLANATORY
NOTE

Incorporate (the "Company") is filing this Form 10-K/A ("Form 10-K/A" or this "Amendment") to amend
our Annual Report on Form 10-K for the nine months ended September 30, 2022, originally filed with the Securities and Exchange Commission
(the "SEC") on March 28, 2023 ("Original Report"), to restate our financial statements and related footnote disclosures
as of and for the nine months ended September 30, 2022 (the "Affected Period"). This Form 10-K/A also amends certain other
Items in the Original Report, as listed in "Items Amended in this Form 10-K/A" below.

 Restatement
Background

 The
Company incorrectly recorded a liability for what it believed was an extension payment associated with its USDA CRADA research contract
as of September 30, 2022. However, the Company was mistaken and there was no additional payment to extend the contract only the amount
originally due which had already been recorded. The error resulted in the overstatement of the Company's current liabilities and
net loss by approximately $246,000.

 Effects
of Restatement

 See
Note 1 to the Notes to consolidated financial statements included in Part II, Item 8 of this Amendment for additional information on
the restatement and the related financial statement effects.

 Items
Amended in this Form 10-K/A

 This
Form 10-K/A presents the Original Report, amended and restated with modifications as necessary to reflect the restatements. The following
items have been amended to reflect the restatement:

 Part
II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

 Part
II, Item 8. Financial Statements and Supplementary Data

 Part
II, Item 9A – Controls and Procedures

 In
addition, the Company's Chief Executive Officer and Chief Financial Officer have provided new certifications dated as of the date
of this filing in connection with this Form 10-K/A.

 TABLE
OF CONTENTS

 Page

 PART I.

 Item
 1.

 Business

 Item
 1A.

 Risk Factors

 Item
 1B.

 Unresolved Staff Comments

 Item
 2.

 Properties

 Item
 3.

 Legal Proceedings

 Item
 4.

 Mine Safety Disclosures

 PART II.

 Item
 5.

 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 Item
 6.

 Selected Financial Data

 Item
 7.

 Management's Discussion and Analysis of Financial Condition and Results of Operation

 Item
 7A.

 Quantitative and Qualitative Disclosures About Market Risk

 Item
 8.

 Financial Statements and Supplementary Data

 Item
 9.

 Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

 Item
 9A.

 Controls and Procedures

 Item
 9B.

 Other Information

 PART III.

 Item
 10.

 Directors, Executive Officers and Corporate Governance

 Item
 11.

 Executive Compensation

 Item
 12.

 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 Item
 13.

 Certain Relationships and Related Transactions, and Director Independence

 Item
 14.

 Principal Accounting Fees and Services

 PART
 IV.

 Item
 15.

 Exhibits, Financial Statement Schedules

 Signatures

 Exhibits

 FORWARD
LOOKING STATEMENTS

 This
Annual Report on Form 10-K contains forward-looking statements within the meaning of Rule 175 of the Securities Act of 1933, as amended,
and Rule 3b-6 of the Securities Act of 1934, as amended, that involve substantial risks and uncertainties. These forward-looking statements
are not historical facts, but rather are based on current expectations, estimates and projections about our industry, our beliefs and
our assumptions. Words such as "anticipate," "expects," "intends," "plans," "believes,"
"seeks" and "estimates" and variations of these words and similar expressions are intended to identify forward-looking
statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some
of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or
forecasted in the forward-looking statements. You should not place undue reliance on these forward-looking statements, which apply only
as of the date of this Form 10-K. Investors should carefully consider all of such risks before making an investment decision with respect
to the Company's stock. The following discussion and analysis should be read in conjunction with our financial statements for Genvor
Incorporated Such discussion represents only the best present assessment from our Management.

 PART
I

 Item
1: Description of Business

Incorporated (the "Company" or "Genvor") was incorporated in Florida on September 26, 2018, as "Allure
Worldwide, Inc.," and as of November 18, 2019, redomiciled to Nevada. On June 24, 2022, the Company changed its name to from "Allure
Worldwide, Inc." to "Genvor Incorporated."

 The
Company was originally formed with the intention of seeking to acquire the assets or shares of an entity actively engaged in business
which generates revenues, in exchange for its securities. On January 11, 2021, the Company entered into an Exchange Agreement (the "Purchase
Agreement") with Genvor Inc., a Delaware corporation ("Genvor") to acquire (the "Acquisition") Genvor.
On March 2, 2022, the Company and Genvor entered into a merger agreement (the "Merger Agreement") to consummate the Acquisition,
and pursuant to which a wholly-owned subsidiary of the Company, Genvor Acquisition Corp., a Delaware corporation, would merge (the "Merger")
with and into Genvor, with each share of Genvor common stock issued immediately prior to the time of the merger automatically converted
into the right to receive one share of common stock of the Company.

 On
May 27, 2022, the Acquisition closed, Merger Subsidiary merged with and into Genvor, each share of Genvor was exchanged for the right
to receive one share of Company common stock, 35,261,871 shares of Company common stock were issued to Genvor's pre-merger shareholders
(the "Merger Shares"), constituting a change of control of the Company, and Genvor became a wholly owned subsidiary of the
Company. As a result of these transactions, the Company had 55,261,871 issued and outstanding common shares upon the closing of the share
exchange with Genvor, and subsequently the Company's original founding shareholders cancelled 18,144,112 shares of Company common
stock in connection with the Acquisition.

 As
a result of the Acquisition, the Company's business plan is that of Genvor, and the Company is developing plant-based defense technology
designed to help farmers achieve global food security.

History

 The
Company's subsidiary, Genvor Inc. was incorporated under the laws of the State of Delaware on April 4, 2019, as "Nexion Biosciences
Inc.," and on January 22, 2020, its name was changed to "Genvor Inc." Genvor Inc. develops plant-based defense technology
designed to help farmers achieve global food security.

May 2019, Genvor Inc. acquired Nexion Biosciences LLC ("NBLLC") from a founder for nominal consideration. NBLLC was formed
in the State of Delaware on December 28, 2018.

technology was developed by two university scientists, Dr. Clayton Yates and Dr. Jesse Jaynes, who shared a mission to develop crop protection
technology designed to defend against crop diseases effecting both animals and humans alike. Genvor's technology is currently being
advanced by the USDA in corn seed varieties and with U.S. Sugar in citrus trees.

headquarters is located at 13155 Noel Road, Suite 900, Dallas, Texas, 75240.

Plan of Operation

 The
United States Food and Agriculture Organization reports that annual global crop losses due to plant pathogens and viruses are now estimated
to exceed $100 billion. Alarming to the FDA are the fungi "Aspergillus Flavus," which produce Aflatoxins, a toxic and carcinogenic
compound known to cause liver cancer in humans and animals. Aspergillus Flavus is also the second leading cause of "aspergillosis"
in humans. Patients infected with Aspergillus flavus often have reduced or compromised immune systems.

 The
U.S. Food and Drug Administration estimates the annual cost of Aflatoxin contamination in the United States at approximately $500 million
through two categories of loss: market rejection and animal health impacts. As a result, the United States Department of Agriculture
(USDA) has imposed strict guidelines for crop inspection and discovery of diseased crops caused by Aflatoxins. Both planted fields and
harvested crops that are found to be contaminated beyond permitted testing levels must be destroyed. As a result, farmers and growers
can be exposed to catastrophic economic losses. This Aflatoxin problem has created a significant opportunity for agricultural companies
who can develop the technology needed to defend against Aflatoxins.

Solution

technology is the only known solution that Genvor is aware of, which Genvor believes provides broad spectrum effectiveness against Aspergillus
Flavus and Aflatoxins. This technology is deliverable by both bioengineered seed trait, as well as through biopesticide application.

 Dr.
Jaynes, one of Genvor's founders, has been on a 30+ year quest to find a global crop solution for defense against Aflatoxins. As
a result of successful testing and collaboration between Dr. Jaynes and the United States Department of Agriculture, Agriculture Research
Service (USDA-ARS), the USDA-ARS awarded Genvor with a Cooperative Research & Development Agreement in August of 2018. The stated
goal of this agreement is to develop and commercialize disease resistant and nutritionally enhanced corn seed varieties using Genvor's
seed trait technology.

 Seed
Traits

 In
the United States, the adoption of crop seeds with enhanced traits has been staggering. Currently, over 90 percent of U.S. corn, cotton
and soybeans are produced using seeds with enhanced traits. Trait fees for these three crops alone represent over $2 billion annually
based on an average trait fee of $13 per acre on approximately 170 million acres. U.S. corn crops alone account for roughly $1.2 billion
of the estimated $2 billion.

 Biopesticides

 Biopesticides
are one of the fastest-growing crop protection market sectors, increasing at twice the compound annual growth rate of the crop protection
market as a whole. Primary drivers of this growth include a rising global demand for organic foods, the trend in the reduction of chemical
residues, stricter import and supermarket standards, shorter pre-harvest intervals, a push for sustainability, and the demand for additional
modes of action for managing resistance. The biopesticide market in north America alone is currently estimated to be over $4.8 billion
annually.

technology is effective with corn seed and is believed by Genvor to be effective with many known crop types, and the technology may be
delivered as a topical spray in the form of a biopesticide.

Incorporated ("Genvor" or the "Company") was incorporated in the State of Florida on September 26, 2018,

 Reports
to Security Holders

 We
intend to furnish our shareholders annual reports containing financial statements audited by our independent registered public accounting
firm and to make available quarterly reports containing unaudited financial statements for each of the first three quarters of each year.
We file Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and Current Reports on Form 8-K with the Securities and Exchange
Commission voluntarily in order to disclose material information regarding the Company to the public. We may also file additional documents
with the Commission if they become necessary in the course of our company's operations.

 The
public may read and copy any materials that we file with the SEC at the SEC's Public Reference Room at 100 F Street, NE, Washington,
D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The
SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that
file electronically with the SEC. The address of that site is www.sec.gov.

 Government
Regulations

 We
believe that we are and will continue to be in compliance in all material respects with applicable statutes and the regulations passed
in the United States. There are no current orders or directions relating to our company with respect to the foregoing laws and regulations.

 Environmental
Regulations

 While
our products and business activities do not currently violate any laws, any regulatory changes that impose additional restrictions or
requirements on us or on our products or potential customers could adversely affect us by increasing our operating costs or decreasing
demand for our products or services, which could have a material adverse effect on our results of operations.

 Employees

 As
of September 30, 2022, we had no full-time employees.

 Property

 The
Company does not own or rent property. The Company's corporate headquarters is provided by the Company's CEO and Director,
Bradley White, at no charge.

 Item
1A. Risk Factors

 As
a smaller reporting company, we are not required to provide the information required by this item.

 Item
1B. Unresolved Staff Comments.

 None.

 Item
2. Properties

 We
do not own any real estate or other properties.

 Item
3. Legal Proceedings

 Management
is not aware of any legal proceedings contemplated by any governmental authority or any other party involving us or our properties. As
of the date of this Annual Report, no director, officer, or affiliate is (i) a party adverse to us in any legal proceeding, or (ii) has
an adverse interest to us in any legal proceedings. Management is not aware of any other legal proceedings pending or that have been
threatened against us or our properties.

 Item
4. Mine Safety Disclosures

 Not
applicable to our Company.

 PART
II

 Item
5. Market for Common Equity and Related Stockholder Matters

 Market
Information

 There
has been no market for our securities. Our common stock is not traded on any exchange or on the over-the-counter market. We hope to have
a market maker file an application with the Financial Industry Regulatory Authority, FINRA for our common stock to be eligible for trading
on OTC Markets. We are in the process of having OTC Markets Group, Inc. do so, but there is no assurance that any such application will
ever be approved or that a trading market will develop, or, if developed, that it will be sustained.

 The
Company's transfer agent is Securities Transfer Corporation, Securities Transfer Corporation 2901 N. Dallas Parkway, Suite 380,
Plano, Texas, 75093, Telephone: (469) 633-0088.

 Dividend
Distributions

 We
have not paid any cash dividends on our common stock and have no present intention of paying any dividends on the shares of our common
stock. Our current policy is to retain earnings, if any, for use in our operations and in the development of our business. Our future
dividend policy will be determined from time to time by our board of directors.

 Securities
authorized for issuance under equity compensation plans

 The
Company does not have a stock option plan.

 Penny
Stock

 Our
common stock is considered "penny stock" under the rules the Securities and Exchange Commission (the "SEC") under
the Securities Exchange Act of 1934. The SEC has adopted rules that regulate broker-dealer practices in connection with transactions
in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain
national securities exchanges or quoted on the NASDAQ Stock Market System, provided that current price and volume information with respect
to transactions in such securities is provided by the exchange or quotation system. The penny stock rules require a broker-dealer, prior
to a transaction in a penny stock, to deliver a standardized risk disclosure document prepared by the Commission, that:

 contains
 a description of the nature and level of risks in the market for penny stocks in both public offerings and secondary trading;

 contains
 a description of the broker's or dealer's duties to the customer and of the rights and remedies available to the customer
 with respect to a violation to such duties or other requirements of Securities' laws; contains a brief, clear, narrative description
 of a dealer market, including bid and ask prices for penny stocks and the significance of the spread between the bid and ask price;

 contains
 a toll-free telephone number for inquiries on disciplinary actions;

 defines
 significant terms in the disclosure document or in the conduct of trading in penny stocks; and

 contains
 such other information and is in such form, including language, type, size and format, as the Commission shall require by rule or
 regulation.

 The
broker-dealer also must provide, prior to effecting any transaction in a penny stock, the customer with:

 bid
 and offer quotations for the penny stock;

 the
 compensation of the broker-dealer and its salesperson in the transaction;

 the
 number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the
 marker for such stock; and

 monthly
 account statements showing the market value of each penny stock held in the customer's account.

 In
addition, the penny stock rules that require that prior to a transaction in a penny stock not otherwise exempt from those rules; the
broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the
purchaser's written acknowledgement of the receipt of a risk disclosure statement, a written agreement to transactions involving
penny stocks, and a signed and dated copy of a written suitably statement.

 These
disclosure requirements may have the effect of reducing the trading activity in the secondary market for our stock.

 Related
Stockholder Matters

 None.

 Purchase
of Equity Securities

 None.

 Item
6. Selected Financial Data

 As
the Company is a "smaller reporting company," this item is inapplicable.

 Item
7. Management's Discussion and Analysis of Financial Condition and Results of Operations

 This
Annual Report on Form 10-K contains forward-looking statements within the meaning of Rule 175 of the Securities Act of 1933, as amended,
and Rule 3b-6 of the Securities Act of 1934, as amended, that involve substantial risks and uncertainties. These forward-looking statements
are not historical facts, but rather are based on current expectations, estimates and projections about our industry, our beliefs, and
our assumptions. Words such as "anticipate," "expects," "intends," "plans," "believes,"
"seeks" and "estimates" and variations of these words and similar expressions are intended to identify forward-looking
statements. These statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some
of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or
forecasted in the forward-looking statements. You should not place undue reliance on these forward-looking statements, which apply only
as of the date of this Form 10-K. Investors should carefully consider all of such risks before making an investment decision with respect
to the Company's stock. The following discussion and analysis should be read in conjunction with our financial statements and summary
of selected financial data for the Company. Such discussion represents only the best present assessment from our Management.

 DESCRIPTION
OF COMPANY

Incorporated (the "Company") was incorporated in Florida on September 26, 2018, as Allure Worldwide, Inc., and as of November
18, 2019, redomiciled to Nevada. On June 24, 2022, the Company changed its name to from Allure Worldwide, Inc. to Genvor Incorporated.

 The
Company was originally formed with the intention of seeking to acquire the assets or shares of an entity actively engaged in business
which generates revenues, in exchange for its securities. On January 11, 2021, the Company entered into an Exchange Agreement (the "Purchase
Agreement") with Genvor Inc., a Delaware corporation ("Genvor") to acquire (the "Acquisition") Genvor.
On March 2, 2022, the Company and Genvor entered into a merger agreement (the "Merger Agreement") to consummate the Acquisition,
and pursuant to which a wholly-owned subsidiary of the Company, Genvor Acquisition Corp., a Delaware corporation, would merge (the "Merger")
with and into Genvor, with each share of Genvor common stock issued immediately prior to the time of the merger automatically converted
into the right to receive one share of common stock of the Company.

 On
May 27, 2022, the Acquisition closed, Merger Subsidiary merged with and into Genvor, each share of Genvor was exchanged for the right
to receive one share of Company common stock, 35,261,871 shares of Company common stock were issued to Genvor's pre-merger shareholders
(the "Merger Shares"), constituting a change of control of the Company, and Genvor became a wholly owned subsidiary of the
Company. As a result of these transactions, the Company had 55,261,871 issued and outstanding common shares upon the closing of the share
exchange with Genvor, and subsequently the Company's original founding shareholders cancelled 18,144,112 shares of Company common
stock in connection with the Acquisition.

 As
a result of the Acquisition, the Company's business plan is that of Genvor, and the Company is developing plant-based defense technology
designed to help farmers achieve global food security.

 The
Company's technology was developed by two university scientists, Dr. Clayton Yates and Dr. Jesse Jaynes, who shared a mission to
develop crop protection technology designed to defend against crop diseases effecting both animals and humans alike. The Company's
technology is currently being advanced by the USDA in corn seed varieties and with U.S. Sugar in citrus trees.

 The
following Management Discussion and Analysis should be read in conjunction with the financial statements and accompanying notes included
in this Form 10-K.

 COMPARISON
OF THE NINE MONTHS ENDED SEPTEMBER 30, 2022, TO THE YEAR ENDED DECEMBER 31, 2021

 Results
of Operations

 The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with the financial
statements and notes thereto for the nine months ended September 30, 2022 and the year ended December 31, 2021, and related management
discussion herein.

 Our
financial statements are stated in U.S. Dollars and are prepared in accordance with generally accepted accounting principles of the United
States ("GAAP").

 Going
Concern Qualification

 Several
conditions and events cast substantial doubt about the Company's ability to continue as a going concern. At September 30, 2022,
the Company had an accumulated deficit of $16,041,937, incurred a net loss of $4,240,109 for the nine months ended September 30, 2022,
requires capital for contemplated operational activities to take place. These conditions raise substantial doubt about the Company's
ability to continue as a going concern. Management's plans with respect to operations include raising additional capital through
sales of equity or debt securities as may be necessary to pursue such business plans and sustain operations until such time as the Company
can merge with or be acquired by another entity. However, there can be no assurance that management will be successful in obtaining additional
funding or in attaining profitable operations. The ability to successfully resolve these factors raises substantial doubt about the Company's
ability to continue as a going concern.

 Our
operating results for the nine months ended September 30, 2022, and year ended December 31, 2021, and the changes between those periods
for the respective items, are summarized as follows:

 Nine Months Ended
30,

 2022

 Year
Ended December 31,

 2021

 Operating loss

 $
 (4,063,881
)

 $
 (3,101,904
)

 Total other income (expense)

 (176,228
)

 (337,620
)

 $
 (4,240,109
)

 $
 (3,439,524
)

 Revenues

 We
did not earn any revenues during the nine months ended September 30, 2022, or the year ended December 31, 2021.

 Operating
Loss

 Our
loss from operations increased to $4,063,881 during the nine months ended September 30, 2022, from an operating loss of $3,101,904 in
the year ended December 31, 2021. The following table presents operating expenses for the nine months ended September 30, 2022, and the
year ended December 31, 2021:

 Nine Months Ended
 30,

 2022

 Year
Ended December 31,

 2021

 Professional fees

 $
 233,153

 $
 89,640

 Payroll related expenses

 120,725

 390,000

 Research and development

 -

 226,448

 Stock-based compensation

 3,512,500

 2,222,961

 Depreciation expense

 1,374

 1,832

 General and administrative expenses

 $
 196,129

 $
 171,023

 Total Operating Expenses

 $
 4,063,881

 $
 3,101,904

 We
realized an increase in professional fees during the nine months ended September 30, 2022 as compared to the year ended December 31,
2021 primarily as a result of increased accounting, audit, and legal expenses incurred during 2022. Stock-based compensation expenses
increased during the nine months ended September 30, 2022 as compared to the year ended December 31, 2021 primarily as a result of the
issuance of shares of common stock.

 Net
Loss

 The
Company incurred a net loss of $4,240,109 during the nine months ended September 30, 2022, as compared to a net loss of $3,439,524 during
the year ended December 31, 2021, as a result of the increased operating expenses during 2022 described above.

 Liquidity
and Capital Resources

 Based
upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve
months. We intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund expenditures
or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There
can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation
of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable
terms or at all.

 Working
Capital

 The
following table presents our working capital position as of September 30, 2022, and December 31, 2021:

 September 30,

 2 022

 December 31,
 2021

 Cash

 $
 296,385

 $
 384,621

 Current Assets

 298,385

 535,952

 Current Liabilities

 1,621,174

 2,449,808

 Working Capital (Deficiency)

 $
 (1,322,789
)

 $
 (1,913,856
)

 The
decrease in working capital deficiency as of September 30, 2022, as compared to December 31, 2021, was primarily due to notes payable
decreasing from $1,632,250 as of December 31, 2021, to $1,100,750 as of September 30, 2022, partially offset by the decrease current
assets as of September 30, 2022, as compared to December 31, 2021.

 Cash
Flow

 We
fund our operations with cash received from issuances of promissory notes and equity as described below.

 Cash
Flows from Operating Activities

 We
did not generate cash flows from operating activities for the nine months ended September 30, 2022, or the year ended December 31, 2021.
For the nine months ended September 30, 2022, and the year ended December 31, 2021, net cash used in operating activities were $553,236
and $663,203, respectively.

 Cash
Flows from Investing Activities

 For
the nine months ended September 30, 2022, and the year ended December 31, 2021, no cash flows were provided by or used in investing activities.

 Cash
Flows from Financing Activities

 For
the nine months ended September 30, 2022, and the year ended December 31, 2021, $465,000 and $889,851, respectively, in net cash was
provided by financing activities. For the nine months ended September 30, 2022, and year ended December 31, 2021, $300,000 and $365,000,
respectively, in cash was provided by notes payable, and $165,000 and $570,005, respectively, in net cash was provided by sales of common
stock.

 Off-Balance
Sheet Arrangements

 The
Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the
Company's financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital
expenditures or capital resources that are material to investors.

 Critical
Accounting Policies

 Use
of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States
of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the reporting period. Actual results could differ from those estimates. Significant estimates in the accompanying financial statements
include the amortization period for intangible assets, valuation and impairment valuation of intangible assets, depreciable lives of
the web site and property and equipment, valuation of warrant and beneficial conversion feature debt discounts, valuation of share-based
payments and the valuation allowance on deferred tax assets.

 Investments
in Equity

 We
measure all equity investments that do not result in consolidation and are not accounted for under the equity method at fair value with
the change in fair value included in net income. We use quoted market prices to determine the fair value of equity securities with readily
determinable fair values. For equity securities without readily determinable fair values, we have elected the measurement alternative
under which we measure these investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes
in orderly transactions for the identical or a similar investment of the same issuer. Management assesses each of these investments on
an individual basis.

 Item
7A. Quantitative and Qualitative Disclosures about Market Risk

 As
the Company is a "smaller reporting company," this item is inapplicable.

 Item
8. Financial Statements and Supplementary Data

 Table
of Contents

 Page

 Report of Independent Registered Public Accounting Firm (PCAOB ID: 76)

 Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021

 Consolidated Statements of Operations for the nine months ended September 30, 2022 and for the year ended December 31, 2021

 Consolidated Statements of Changes in Shareholders' Deficit for the nine months ended September 30, 2022 and for the year ended December 31, 2021

 Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and for the year ended December 31, 2021

 Notes to the Consolidated Financial Statements

 Your
Vision Our Focus

 Report
of Independent Registered Public Accounting Firm

 Board
of Directors and Stockholders

 Opinion
on the Financial Statements

 We
have audited the accompanying consolidated balance sheets of Genvor Incorporated as of September 30, 2022 and December 31, 2021, and
the related consolidated statements of operations, changes in stockholders' deficit, and cash flows for the nine months ended September
30, 2022 and year ended December 31, 2021, and the related notes (collectively referred to as the "financial statements").
In our opinion, the financial statements present fairly, in all material respects, the financial position of Genvor Incorporated as of
September 30, 2022 and December 31, 2021, and the results of its operations and its cash flows for the nine months ended September 30,
2022 and year ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.

 Going
Concern

 The
accompanying financial statements have been prepared assuming that the entity will continue as a going concern. As discussed in Note
1 to the financial statements, the entity has suffered recurring losses from operations and has a net capital deficiency that raise substantial
doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note
1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 Basis
for Opinion

 These
financial statements are the responsibility of the entity's management. Our responsibility is to express an opinion on these financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) ("PCAOB") and are required to be independent with respect to Genvor Incorporated in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Genvor
Incorporated is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the entity's internal control over financial reporting. Accordingly, we express no such opinion.

 Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.

 /s/
 Turner, Stone & Company, L.L.P.

 We
 have served as Genvor Incorporated's auditor since 2020.

 Dallas,
 Texas

 March
 28, 2023

 Turner,
 Stone & Company, L.L.P.

 Accountants
 and Consultants

 12700
 Park Central Drive, Suite

 1400

 Dallas,
 Texas 75251

 Telephone:
 972-239-1660

 Facsimile:
 972-239-1665

 Toll
 Free: 877-853-4195

 Website
turnerstone.com

 F- 1

 (f/k/a
Allure Worldwide, Inc.)

 Consolidated
Balance Sheets

 September 30,

 December 31,

 2022

 2021

 (as restated)

 ASSETS

 Current assets:

 Cash

 $
 296,385

 $
 384,621

 Prepaid expenses

 -

 1,331

 Prepaid costs for reverse capitalization

 -

 Other current assets

 2,000

 -

 Total current assets

 298,385

 535,952

 Fixed assets, net

 17,565

 18,939

 Receivables from related parties

 -

 2,053

 Total assets

 $
 315,951

 $
 556,944

 LIABILITIES AND STOCKHOLDERS' DEFICIT

 Current liabilities:

 Notes payable

 $
 1,052,000

 $
 1,632,250

 Accounts payable and accrued expenses

 270,178

 571,158

 Due to related party

 3,846

 -

 SBA loan

 48,750

 -

 USDA CRADA liability

 246,400

 246,400

 Total current liabilities

 1,621,174

 2,449,808

 Non-current liabilities:

 Convertible notes payable, net of discounts

 89,221

 -

 Notes payable, net of discounts

 -

 344,167

 Total non-current liabilities

 89,221

 344,167

 Total liabilities

 1,710,395

 2,793,975

 Commitments and contingencies (Note 6)

 -

 -

 Stockholders' deficit:

 Preferred stock, $ 0.001 par value, 20,000,000 shares authorized, 9 and 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively

 -

 -

 Common stock, $ 0.001 par value, 300,000,000 shares authorized, 38,678,155 and 26,025,020 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively

 38,678

 26,025

 Additional paid-in capital

 14,608,815

 9,538,772

 Accumulated deficit

)

 ( 11,801,828
)

 Total stockholders' deficit

 ( 1,394,444
)

 ( 2,237,031
)

 Total liabilities and stockholders' deficit

 $
 315,951

 $
 556,944

 The
accompanying notes are an integral part of these consolidated financial statements.

 F- 2

 (f/k/a
Allure Worldwide, Inc.)

 Consolidated
Statements of Operations

 Nine Months

 Year

 Ended

 Ended

 September 30,

 December 31,

 2022

 2021

 (as restated)

 Revenue

 $
 -

 $
 -

 Operating expenses

 Professional fees

 233,153

 89,640

 Payroll related expenses

 120,725

 390,000

 Research and development

 -

 226,448

 Stock-based compensation

 3,512,500

 2,222,961

 Depreciation expense

 1,374

 1,832

 Other general and administrative expenses

 196,129

 171,023

 Total operating expenses

 4,063,881

 3,101,904

 Operating loss

 ( 4,063,881
)

 ( 3,101,904
)

 Other income (expense)

 Interest expense

 ( 51,117
)

 ( 102,792
)

 Penalties

 ( 90,000
)

 ( 120,000
)

 Beneficial conversion feature

 ( 30,111
)

 -

 Loss on Agromed acquisition failure

 -

 ( 114,828
)

 Loss on settlement of liabilities

 ( 5,000
)

 -

 Total other income (expense)

 ( 176,228
)

 ( 337,620
)

 $
)

 $
 ( 3,439,524
)

 Basic and diluted net loss per common share

 $
 ( 0.13
)

 $
 ( 0.15
)

 Basic and diluted weighted average common shares outstanding

 32,437,505

 22,493,382

 The
accompanying notes are an integral part of these consolidated financial statements.

 F- 3

 (f/k/a
Allure Worldwide, Inc.)

 Consolidated
Statements of Changes in Stockholders' Deficit

 For
the Nine Months Ended September 30, 2022 and the Year Ended December 31, 2021

 Amount

 Amount

 Capital

 Deficit

 Total

 Series A

 Additional

 Accumu-

 Preferred Stock

 Paid-in

 lated

 Amount

 Amount

 Capital

 Deficit

 Total

 Allure balance, December 31, 2020

 -

 $
 -

 20,000,000

 $
 2,000

 $
 6,773,677

 $
 ( 8,333,278
)

 $
 ( 1,557,601
)

 Recapitalization / RTO impact

 -

 -

 -

 18,000

 ( 21,846
)

 ( 29,026
)

 ( 32,872
)

 Balance, December 31, 2020

 -

 $
 -

 20,000,000

 $
 20,000

 $
 6,751,831

 $
 ( 8,362,304
)

 $
 ( 1,590,473
)

 Common stock issued for services

 -

 -

 3,150,000

 3,150

 1,519,863

 -

 1,523,012

 Exercise of options

 -

 -

 1,400,000

 1,400

 ( 1,400
)

 -

 Common stock issued for cash

 -

 -

 1,475,020

 1,475

 568,530

 570,005

 Common stock options issued for services

 -

 -

 -

 -

 699,948

 -

 699,948

 Net loss for the period ended December 31, 2021

 -

 -

 -

 -

 -

 ( 3,439,524
)

 ( 3,439,524
)

 Balance, December 31, 2021

 -

 $
 -

 26,025,020

 $
 26,025

 $
 9,538,772

 $
 ( 11,801,828
)

 ( 2,237,031
)

 Balance value

 -

 $
 -

 26,025,020

 $
 26,025

 $
 9,538,772

 $
 ( 11,801,828
)

 ( 2,237,031
)

 Common stock issued for services

 -

 -

 6,525,000

 6,525

 3,505,975

 -

 3,512,500

 Common stock issued for cash

 -

 -

 305,000

 164,970

 -

 165,275

 Common stock issued for debt conversion

 -

 -

 2,622,647

 2,622

 1,232,933

 -

 1,235,555

 Founder shares issued

 -

 -

 1,855,888

 1,856

 ( 1,856
)

 -

 -

 Payment for reverse capitalization

 -

 -

 -

 -

 ( 150,000
)

 -

 ( 150,000
)

 Issuance of common stock to prior S-1 investors

 -

 -

 975,000

 48,750

 -

 49,725

 Issuance of common stock for note receivable

 -

 -

 99,600

 ( 100
)

 -

 -

 Issuance of common stock for 2021 SPA

 -

 -

 50,000

 ( 50
)

 -

 -

 Issuance of common stock for settlements

 -

 -

 50,000

 ( 50
)

 -

 -

 Beneficial conversion feature

 -

 -

 -

 -

 269,916

 -

 269,916

 419 fund raising services

 -

 -

 170,000

 ( 170
)

 -

 -

 Issuance of preferred stock

 -

 -

 -

 -

 -

 -

 Net loss for the period ended September 30, 2022 (as restated)

 -

 -

 -

 -

 -

)

)

 Net loss for the period ended

 -

 -

 -

 -

 -

)

)

 Balance, September 30, 2022 (as restated)

 $
 -

 38,678,155

 $
 38,678

 $
 14,608,815

 $
)

 $
 ( 1,394,444
)

 Balance value

 $
 -

 38,678,155

 $
 38,678

 $
 14,608,815

 $
)

 $
 ( 1,394,444
)

 The
accompanying notes are an integral part of these consolidated financial statements.

 F- 4

 (f/k/a
Allure Worldwide, Inc.)

 Consolidated
Statements of Cash Flow

 Nine
 Months

 Year

 Ended

 Ended

 September 30,

 December 31,

 2022

 2021

 (as restated)

 Cash flows from operating activities:

 $
)

 $
 ( 3,439,524
)

 Adjustments to reconcile net loss to net cash used in operating activities:

 Depreciation expense

 1,374

 1,832

 Interest expense capitalized into notes payable

 -

 10,000

 Late fee capitalized into notes payable

 90,000

 120,000

 Loss on Agromed acquisition failure

 -

 114,828

 Stock-based compensation

 3,512,500

 2,222,961

 Beneficial conversion feature amortization

 30,111

 -

 Amortization of debt discount

 -

 11,667

 Loss on settlement of liabilities

 5,000

 -

 Changes in assets and liabilities:

 Prepaid expenses

 1,331

 ( 1,331
)

 Prepaid costs for reverse capitalization

 ( 100,000
)

 Other current assets

 ( 2,000
)

 -

 Receivables from related parties

 2,053

 -

 Accounts payable and accrued expenses

 ( 107,342
)

 323,564

 Due to related party

 3,846

 -

 USDA CRADA liability

 -

 72,800

 Net cash used in operating activities

 ( 553,236
)

 ( 663,203
)

 Cash flows from financing activities:

 Proceeds from notes payable

 300,000

 365,000

 Payments of notes payable

 -

 ( 6,000
)

 Payments of receivable from related parties

 -

 ( 25,579
)

 Proceeds from sale of common stock

 165,000

 570,005

 Repayments of advances payable from related parties

 -

 ( 3,575
)

 Net cash provided by financing activities

 465,000

 899,851

 Net increase (decrease) in cash

 ( 88,236
)

 236,648

 Cash at beginning of period

 384,621

 147,973

 Cash at end of period

 $
 296,385

 $
 384,621

 Cash paid for interest

 $
 -

 $
 -

 Cash paid for taxes

 $
 -

 $
 -

 Non-cash investing and financing activities:

 Discount on notes payable

 $
 269,916

 $
 35,000

 Right of use, lease asset and liability

 $
 -

 $
 13,480

 Issuance of common stock for debt conversion

 $
 1,235,555

 $
 -

 Issuance of common stock for debt settlement

 $
 49,725

 $
 -

 Fundraising services

 $
 170,000

 $
 -

 Prepaid costs for reverse capitalization recognized in additional paid-in capital

 $

 $
 -

 The
accompanying notes are an integral part of these consolidated financial statements.

 F- 5

 Notes
to Consolidated Financial Statements

30, 2022

 NOTE
1 – ORGANIZATION AND BASIS OF PRESENTATION

 Company
Background

 On
May 27, 2022, Genvor Incorporated, formerly known as Allure Worldwide, Inc. (the "Company" or "Genvor" or "we"),
a Nevada corporation, Genvor Acquisition, Corp., a Delaware corporation and a wholly owned subsidiary of the Company ("Merger Sub"),
and Genvor Inc., a Delaware corporation ("Old Genvor"), completed their previously announced merger transaction pursuant
to which the Company acquired Old Genvor (the "Acquisition"), and Old Genvor became a wholly-owned subsidiary of the Company.
The Acquisition was completed pursuant to an Exchange Agreement, dated as of January 11, 2021 (the "Acquisition Agreement"),
pursuant to which Old Genvor was to be acquired by the Company as its wholly owned subsidiary and each share of Old Genvor common stock
would be exchanged for a share of the Company's common stock, and a merger agreement, dated March 2, 2022 (the "Merger Agreement"),
pursuant to which Merger Sub merged with and into Old Genvor, with Old Genvor continuing as a wholly owned subsidiary of the Company
and the surviving corporation of the merger, and each share of Old Genvor being converted into the right to receive a share of the Company
(the "Merger"). After closing of the Merger, the Company was renamed "Genvor Incorporated". Genvor develops plant-based
defense technology designed to help farmers achieve global food security.

May 2019, Old Genvor acquired Nexion Biosciences LLC ("NBLLC") from a founder for nominal consideration as a wholly owned
subsidiary. NBLLC was formed in the state of Delaware on December 28, 2018. The consolidated financial statements of the Company include
the accounts of Genvor Incorporated, Old Genvor, and its wholly owned subsidiary NBLLC. Intercompany accounts and transactions have been
eliminated upon consolidation.

 Nature
of Operations

 The
Company's business plan is developing plant-based defense technology designed to help farmers achieve global food security. The
Company's technology was developed by two university scientists, Dr. Clayton Yates and Dr. Jesse Jaynes, who shared a mission to
develop crop protection technology designed to defend against crop diseases effecting both animals and humans alike.

 Basis
of Presentation

 The
Company follows the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America
and has a year-end of September 30. The wholly owned subsidiary has a year-end of December 31.

 Due
to the different fiscal year-ends, the consolidated financial statements will reflect the balance sheets and the statements of changes
in stockholders' deficit dates of September 30, 2022, and December 31, 2021, whereas the statements of operations and statements
of cash flows are for the nine months ended September 30, 2022, and the year ended December 31, 2021.

 Principles
of Consolidation

 The
consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances
and transactions have been eliminated in the consolidation. The consolidated financial statements included herein, presented in accordance
with United States generally accepted accounting principles ("GAAP") and stated in United States dollars, have been prepared
by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission.

 F- 6

 Liquidity
and Going Concern

 The
accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates,
among other things, the realization of assets and satisfaction of liabilities in the normal course of business. At September 30, 2022,
the Company had an accumulated deficit of $ 16,041,937. For the nine months ended September 30, 2022, the Company recognized a net loss
of $ 4,240,109 and had net cash used in operating activities of $ 553,236, with no revenues earned, and limited operational history. These
matters, among others, raise substantial doubt about the Company's ability to continue as a going concern.

 While
the Company is currently developing its products and technologies, the Company's cash position may not be significant enough to
support the Company's daily operations. Management intends to raise additional funds by way of additional public and/or private
offerings of its stock. Management believes that the actions presently being taken to further implement its business plan, develop its
products and technologies, and generate revenues should provide the opportunity for the Company to continue as a going concern. While
the Company believes in the viability of its strategy to generate revenues and in its ability to raise additional funds in the future,
there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company's
ability to further implement its business plan and generate cash flows from financing activities or operating activities. The financial
statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 Restatement
of Previously Issued Financial Statements

 The
Company has restated the accompanying financial statements for the nine months ended September 30, 2022, along with certain notes to
such restated financial statements. The adjustments recorded were related to the correction of an error identified by management. The
nature and impact of this adjustment on the Company's previously issued financial statements is summarized as follows and the effects
by impacted line items are detailed in the tables below. Impacted amounts and associated disclosures are restated within the accompanying
notes to the financial statements.

 The
Company incorrectly recorded a liability for what it believed was an extension payment associated with its USDA CRADA research contract
as of September 30, 2022. However, the Company was mistaken and there was no additional payment to extend the contract only the amount
originally due which had already been recorded. The error resulted in the overstatement of the Company's current liabilities and
net loss by approximately $ 246,000.

 The
following tables summarize the effect of the restatement on each financial statement line items as of and for the nine months ended September
30, 2022.

OF RESTATEMENT

 As previously

 As

 Reported

 Adjustments

 Restated

 Consolidated Balance Sheets as of September 30, 2022

 Accounts payable and accrued expenses

 $
 516,658

 $
)

 $
 270,178

 Total current liabilities

 $
 1,867,654

 $
)

 $
 1,621,174

 Total liabilities

 $
 1,956,875

 $
)

 $
 1,710,395

 Accumulated deficit

 $
 ( 16,288,417
)

 $

 $
)

 Total stockholders' deficit

 $
 ( 1,640,924
)

 $

 $
 ( 1,394,444
)

 Total liabilities and stockholders' deficit

 $
 315,951

 $
 -

 $
 315,951

 Consolidated Statement of Operations for the nine months ended September 30, 2022

 Research and development

 $

 $
)

 $
 -

 Total operating expenses

 $
 4,310,361

 $
)

 $
 4,063,881

 Operating loss

 $
 ( 4,310,361
)

 $

 $
 ( 4,063,881
)

 $
 ( 4,486,589
)

 $

 $
)

 Basic and diluted net loss per common share

 $
 ( 0.14
)

 $
 0.01

 $
 ( 0.13
)

 Basic and diluted weighted average common shares outstanding

 $
 32,437,505

 $
 32,437,505

 Consolidated Statement of Cash flows for the nine months ended September 30, 2022

 $
 ( 4,486,589
)

 $

 $
)

 Accounts payable and accrued expenses

 $
 139,138

 $
)

 $
 ( 107,342
)

 Consolidated Statements of Changes in Stockholders' Deficit for the nine months ended September 30, 2022

 $
 ( 4,486,589
)

 $

 $
)

 Accumulated deficit

 $
 ( 16,288,417
)

 $

 $
)

 NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 Use
of Estimates

 The
preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent
liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual
results could differ from those estimates.

 Cash
Flow Reporting

 The
Company follows Accounting Standards Codification ("ASC 230"), Statement of Cash Flows, for cash flow reporting, classifies
cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions
of each category, and uses the indirect or reconciliation method ("indirect method") as defined by ASC 230, Statement of
Cash Flows, to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating
activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future
operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and
payments.

 Cash

 Cash
is comprised of cash balances. Cash is held at major financial institutions and is subject to credit risk to the extent that those balances
exceed applicable Federal Deposit Insurance Corporation ("FDIC") insurance amounts of $ 250,000. From time to time, the Company
has certain cash balances, including restricted cash, that may exceed insured limits. The Company utilizes large banking institutions
that are reputable therefore mitigating the risks.

 The
Company maintains its cash balances at one financial institution that is insured by the Federal Deposit Insurance Corporation. At September
30, 2022, $ 46,385 of the Company's cash balances were in excess of federally insured limits.

 Fixed
Assets

 Furniture
and equipment are stated at cost. Depreciation is provided by the straight-line method over the useful lives of the related assets, approximately
seven years. Expenditures for minor enhancements and maintenance are expensed as incurred.

 F- 7

 Stock-Based
Compensation

 The
Company accounts for stock-based instruments issued to employees in accordance with ASC Topic 718, Compensation – Stock Compensation,
and Certain Redeemable Financial Instruments. ASC Topic 718 requires companies to recognize in the statement of operations the grant-date
fair value of stock options and other equity-based compensation issued to employees. The value of the portion of an award that is ultimately
expected to vest is recognized as an expense over the requisite service periods using the straight-line attribution method.

 Fair
Value of Financial Instruments

 The
book values of cash, accounts receivable, and accounts payable approximate their respective fair values due to the short-term nature
of these instruments. The fair value hierarchy under GAAP distinguishes between assumptions based on market data (observable inputs)
and an entity's own assumptions (unobservable inputs).

 The
hierarchy consists of three levels

 Level
 one — Quoted market prices in active markets for identical assets or liabilities;

 Level
 two — Inputs other than level one inputs that are either directly or indirectly observable; and

 Level
 three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect
 those assumptions that a market participant would use.

 Determining
which category an asset or liability falls within the hierarchy requires significant judgment. We evaluate our hierarchy disclosures
each quarter.

 Long-lived
Assets

 The
Company's long-lived assets and other assets (consisting of furniture, equipment and a patent) are reviewed for impairment in accordance
with the guidance of the ASC 360, Property, Plant, and Equipment, and ASC 205, Presentation of Financial Statements. The
Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that
the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of
the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair
value. Impairment evaluations involve management's estimates on asset useful lives and future cash flows. Actual useful lives and
cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial
positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values
and third-party independent appraisals, as considered necessary. During the nine months ended September 30, 2022, and the year ended
December 31, 2021, the Company had not experienced impairment losses on its long-lived assets.

 Research
and Development

 The
Company expenses the cost of research and development as incurred. Research and development expenses consist primarily of professional
service costs associated with the development of the plant-based defense technology products. For the nine months ended September 30,
2022, and the year ended December 31, 2021, the Company had $ 0 and $ 226,448 in research and development expenses, respectively.

 Patents

 Any
patent costs for internally developed patents will be expensed as incurred. Costs to maintain and defend patents are recorded as administrative
expenses in the statement of operations.

 Purchased
patents are recorded at cost and reviewed for impairment in accordance with the guidance of the ASC 360, Property, Plant, and Equipment,
and ASC 205, Presentation of Financial Statements.

 F- 8

 Income
Taxes

 The
Company accounts for income taxes in accordance with FASB ASC 740, Income Taxes. Deferred tax assets and liabilities are recognized
for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets
and liabilities and loss carryforwards and their respective tax bases.

 Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those
temporary differences are expected to be recovered or settled.

 The
effect of a change in tax rules on deferred tax assets and liabilities is recognized in operations in the year of change. A valuation
allowance is recorded when it is "more likely-than-not" that a deferred tax asset will not be realized.

 Tax
benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position
taken on an income tax return. The Company has no liability for uncertain tax positions as of September 30, 2022. Interest and penalties
in any, related to unrecognized tax benefits would be recognized as interest expense. The Company does not have any accrued interest
or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the nine months ended
September 30, 2022.

 Stock-Based
Compensation

 The
Company measures compensation cost for all employee stock-based awards at their fair values on the date of grant. Stock-based awards
issued to non-employees are measured at their fair values on the date of grant and are re-measured at each reporting period through their
vesting dates, as applicable. The fair value of stock-based awards is recognized as expense over the service period, net of estimated
forfeitures, using the straight-line method.

 Loss
Per Share of Common Stock

 Basic
net loss per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share ("EPS")
include additional dilution from common stock equivalents, such as stock issuable pursuant to the exercise of stock options, warrants
and convertible notes. Common stock equivalents are not included in the computation of diluted earnings per share when the Company reports
a loss because to do so would be anti-dilutive for periods presented. The Company had total potential additional dilutive securities
outstanding at September 30, 2022 and December 31, 2021 of $ 300,000 and $ 0, respectively.

 Recent
Accounting Pronouncements

 In
August 2020, the FASB issued ASU 2020-06, Debt with Conversion and Other Options, which simplifies accounting for convertible
instruments. The new guidance eliminates two of the three models in ASC 470-20 that require separating embedded conversion features from
convertible instruments. The guidance also addresses how convertible instruments are accounted for in the diluted earnings per share
calculation. The guidance is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact
of ASU 2020-06 on its consolidated financial statements.

 Recently
Issued Accounting Standards: Management does not believe that any recently issued, but not yet effective, accounting standards if currently
adopted would have a material effect on the accompanying financial statements.

 F- 9

 NOTE
3 – BORROWINGS

 Commercial
Loan

 On
April 9, 2020, the Company received a loan from the Small Business Administration pursuant to the Paycheck Protection Program (PPP) in
the principal amount of $ 48,750. The note bears interest at a variable rate of approximately 1 % and matured in April 2022; and it is
currently in default. Forgiveness for the loan was applied for and is pending. The principal amount of the loan was based on the consulting
agreement salary between Nexion Biosciences, Inc., organized in the state of Florida (NBFL) (a related party) and the CEO.

 Payable
for Patent

 On
August 22, 2020, the Company's subsidiary, Genvor Inc., completed an acquisition of Agromed LLC ("Agromed") in a transaction
accounted for under the asset purchase method of accounting, whereby the assets acquired and the liabilities, if any assumed, are to
be valued at fair value, and compared to the fair value of the consideration given to identify if there are any identifiable intangible
assets to be recognized as a result of the transaction. Based on ASC 805, the Company first performed a screen test; determining that
substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset. Agromed only held one
patent and two applications for patents and had no sales, employees, or customers as of the acquisition date. Accordingly, the assets
acquired are not considered a business and the recorded cost of the acquisition was based upon the fair value of the assets acquired.
As consideration for Agromed, the Company was to pay $ 150,000 by March 31, 2021, and issue 230,000 shares of the Company's common
stock, which shares were issued and valued at $ 114,828. Accordingly, the patent was recorded at $ 264,828 on the date of acquisition.
Subsequently, it was discovered that the patent had been transferred to another party prior to August 2020. Such transfer had not been
recorded with the United States Patent and Trademark Office and therefore neither the Company nor the seller were aware of the seller
at the time of the acquisition. As a result, the Company is no longer honoring the agreement to pay $ 150,000 but decided to let the seller
retain the shares. The $ 150,000 note payable was written off along with the patent during the year ended December 31, 2021, resulting
in a loss on the failed acquisition of $ 114,828 for the year ended December 31, 2021.

 Notes
Payable

 From
time to time, the Company's subsidiary, Genvor Inc., enters into unsecured notes payable with individual investors. Only Noteholder
E (below) has security in the form of a personal guarantee by the CEO and prior consultant (Note 6). The terms of these notes are listed
below. Several of the notes are convertible into shares of the Company's common stock as detailed in the following schedule.

OF CONVERTIBLE NOTES PAYABLE

 Balance

 Convertible

 Interest

 Loan

 into

 Noteholder

 Origination

 Maturity

 Rate

 Balance

 Shares (c)

 Noteholder A (a)

 2019

 12/31/2021

 %

 $
 217,000

 N/A

 Noteholder B (a)

 3/19/2019

 4/29/2019

 %

 450,000

 N/A

 Noteholder C (a)

 3/1/2019

 2/29/2020

 %

 32,500

 N/A

 Noteholder D (d)

 4/29/2019

 unspecified

 %

 300,000

 30,000

 Noteholder E (a)

 8/1/2019

 8/31/2019

 %

 37,500

 N/A

 Noteholder F (a)(b)

 2/27/2020

 4/30/2020

 %

 2,500

 5,000

 Noteholder G

 8/3/2021

 8/3/2023

 %

 12,500

 25,000

 Noteholder H (e)

 6/27/2022

 6/27/2024

 %

 300,000

 1,000,000

 1,352,000

 1,060,000

 (d) Debt discount

 ( 210,779
)

 $
 1,141,221

 (a) Past due at September 30, 2022

 (b) Note is payable in a combination of $ 2,500 to $ 6,000 in cash and 5,000 to 15,000 share of common stock

 (c) Convertible into common stock of the subsidiary, Genvor Inc.

 (d) Debt discount

 (e) Noteholder is a shareholder of the
 Company.

 The
notes do not have default provisions except Noteholder B receives a default penalty of $ 10,000 each month the note goes unpaid.

 F- 10

the nine months ended September 30, 2022, $ 989,000 principal and $ 146,946 interest was converted into 2,316,147 common stock shares of
the Company. One note holder had a change in settlement terms, resulting in the recognition of $ 5,000 loss on debt settlement in the
accompanying statement of operations for the nine months ended September 30, 2022.

 Future
maturities of the notes payable are as follows:

OF FUTURE MATURITIES

 2023

 $
 12,500

 2024

 $
 300,000

 Interest
expense totaled $ 141,117 and $ 222,792, respectively, for the nine months ended September 30, 2022, and the year ended December 31, 2021,
including default penalties. Late fees totaled $ 90,000 and $ 120,000, respectively, for the nine months ended September 30, 2022, and
the year ended December 31, 2021.

 NOTE
4 – STOCKHOLDERS' DEFICIT

 Preferred
Stock

 The
authorized preferred stock of the Company consists of 20,000,000 shares with a $ 0.001 par value.

 On
August 10, 2022, the Company designated 10 shares of its preferred stock as Series A Preferred Stock ("Series A"). Each share
of Series A entitles the holder to ten million (10,000,000) votes on all matters submitted to a vote of the stockholders of the Corporation.
When and as any dividend or distribution is declared or paid by the Company on the common stock, the Series A holders are entitled to
participate in such dividend or distribution. Each Series A share is convertible, at the option of the holder, into one share of fully
paid and non-assessable common stock. Upon any liquidation, dissolution, or winding-up of the Company, the Series A holders are entitled
to receive out the assets of the Company, for each share of Series A, an amount equal to par value before any distribution or payment
shall be made to the holder of any junior securities (including common stock and all other equity or equity equivalent securities of
the Company).

 As
of September 30, 2022, and December 31, 2021, there were 9 and 0 shares of preferred stock issued and outstanding, respectively. The
preferred stock was issued on August 16, 2022, as follows: Bradley White (Chief Executive Officer), 3 shares; Dr. Clayton Yates (Chief
Scientific Officer and Chairman), 3 shares; and Dr. Jesse Jaynes (Chief Research Officer and Director), 3 shares. See Note 7.

 On
October 19, 2022, the Company filed a Certificate of Designation with the State of Nevada to designate its Series B Preferred Stock ("Series
B"). The designation authorized 2,500,000 shares of Series B. Each share of Series B shall have 10 votes on all matters submitted
to a vote of the stockholders of the Company. Each share of Series B is convertible into 10 shares of common stock of the Company. See
Note 10.

 Common
Stock

 The
authorized common stock of the Company consists of 300,000,000 shares with a $ 0.001 par value. All common stock shares are non-assessable
and have one vote per share.

 On
April 21, 2022, the Company issued 569 shares of common stock to an individual under a transfer and exchange agreement for a note receivable
held in NBFL (see Note 3). At the transfer date, the latest sale of common stock was at $ 0.50, accordingly the shares were valued at
$ 285, and the note was written off since NBFL has since dissolved.

 In
connection with the Merger (see Notes 1 and 8), the founding shareholders of the Company cancelled 18,144,112 shares of common stock,
retaining 5%, or 1,855,888 shares of common stock, as of June 30, 2022. The cancellation is presented in the accompanying statements
of changes in stockholders' deficit within the line item "Retroactive application of recapitalization."

 F- 11

July 2022, the Company entered into a transfer and exchange agreement with an individual to issue 99,600 shares of common stock for the
note receivable held in NBFL. Since NBFL has minimal assets and was dissolved during the year ended December 31, 2019, the note receivable
was immediately written-off. Based on the latest SPA price per share, the stock was valued at $ 1.00 per share, or $ 99,600.

 On
September 8, 2022, the Company issued 100,000 shares of common stock to a prior Nexion contractor. This was in regard to a claim against
the predecessor management and the Company opted as a settlement to issue the common stock.

Issued for Services

the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company issued 751,500 and 2,650,000 shares of common
stock, respectively, for business advisory services received, valued at $ 325,750 and $ 1,325,323, respectively.

 On
February 18, 2022, the Company issued 20,000 shares of common stock, valued at $ 10,000 (based on the latest third-party sale of common
stock) to an investor for stock compensation. Additionally, 5,000 shares were issued to a debt holder as incentive, valued at $ 2,500
(based on the latest third-party sale of common stock), recorded in interest expense in the accompanying consolidated statement of operations
for the nine months ended September 30, 2022.

 On
March 8, 2022, the Company issued 2,000,000 shares of common stock to each of its three directors, for a total of 6,000,000 shares issued
valued at $ 3,000,000 (based on the latest third-party sale of common stock). The issuances are recorded in stock compensation in the
accompanying consolidated statement of operations.

April 2022, the Company issued 5,000 shares of common stock to a consultant valued at $ 2,500 and recorded in stock compensation in the
accompanying consolidated statement of operations.

 On
May 27, 2022, the Company issued 500,000 shares of common stock for consulting services. Based on the latest third-party sale of common
stock, this resulted in $ 500,000 stock-based compensation.

 On
September 13, 2022, the Company issued 170,000 shares of common stock to Scott Gann for services.

 Stock
Issued for Cash

 From
October through December 2021, the Company entered into fourteen stock purchase agreements ("SPA") for the issuance of a
total of 1,475,020 shares of common stock at prices ranging from $ 0.40 -$ 0.50. The proceeds received under these SPAs totaled $ 570,005.

January and February 2022, the Company entered into six SPAs for the issuance of a total of 280,000 shares of common stock at $ 0.50.
The proceeds received under these SPAs totaled $ 140,000.

 On
May 12, 2022, the Company entered into an SPA for the issuance of 25,000 shares of common stock for $ 25,000, or $ 1.00 per share.

July 2022, the Company issued 975,000 common stock shares to the prior S-1 investors pursuant to their subscription agreements.

July 2022, the Company issued 50,000 shares of common stock to a shareholder pursuant to a December 2021 SPA.

 F- 12

 Stock
Options and Warrants

2019, as an inducement for debt, the Company issued a stock option to Noteholder E for 10,000 shares of common stock at the time of the
Company's initial public offering ("IPO"). The cost of the option was $ 1.00 and provides for a 50% discount to the
initial opening stock price. Since the IPO has yet to take place and the Company had minimal assets at the time of issuance, the option
was valued at $ 0.

 On
January 4, 2021, the Company entered into a consulting agreement for product development and marketing services. As part of the agreement,
 600,000 option shares were issued at signing. An additional 100,000 option shares are earned monthly through August 2021. Although the
IPO is still pending, since the Company sold warrants at $.50 during 2020, these options were valued at $.50. On December 20, 2021, the
consultant elected to convert all 1,400,000 option shares into 1,400,000 shares of common stock.

 The
Company estimated the fair value of the 2021 options based on weighted probabilities of assumptions used in the Black Scholes pricing
model. At issuance, the fair value of the options was estimated using the following weighted-average inputs: the price of the Company's
common stock of $ 0.50; a risk-free interest rate of 0.10 % and expected volatility of the Company's common stock of 500 %, an exercise
price of $.0001, and terms under one year.

 NOTE
5 – FEDERAL INCOME TAX

 As
of September 30, 2022, and December 31, 2021, the Company has net operating loss carry forwards of $ 2,572,885 and $ 2,343,000, respectively,
which may be available to reduce future years' taxable income through 2042. The Company's net operating loss carry forwards
may be subject to annual limitations, which could reduce or defer the utilization of the losses as a result of an ownership change as
defined in Section 382 of the Internal Revenue Code.

 The
Company's tax expense differs from the "expected" tax expense for Federal income tax purposes (computed by applying
the United States Federal tax rate of 21 % to loss before taxes for fiscal year 2022 and 2021), as follows:

OF INCOME TAX EXPENSE

 30,

 December
 31,

 2022

 2021

 Tax
 expense (benefit) at the statutory rate

 $
 ( 204,559
)

 $
 ( 255,478
)

 State
 income taxes, net of federal income tax benefit

 ( 25,326
)

 ( 31,631
)

 Change
 in valuation allowance

 229,885

 287,109

 Total

 $
 -

 $
 -

 The
tax effects of the temporary differences between reportable financial statement income and taxable income are recognized as deferred
tax assets and liabilities.

 The
tax years 2022 and 2021 remains open for examination by federal agencies and other jurisdictions in which it operates.

 The
tax effect of significant components of the Company's deferred tax assets and liabilities at September 30, 2022 and December 31,
2021, are as follows:

OF DEFERRED TAX ASSETS AND LIABILITIES

 30,

 December
 31,

 2022

 2021

 Net
 operating loss carryforward

 $
 2,572,885

 $
 2,343,000

 Total
 gross deferred tax assets

 2,572,885

 2,343,000

 Less:
 Deferred tax asset valuation allowance

 ( 2,572,885
)

 ( 2,343,000
)

 Total
 net deferred taxes

 $
 -

 $
 -

 In
assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all
of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of
future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal
of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.

 Because
of the historical earnings history of the Company, the net deferred tax assets for 2022 and 2021 were fully offset by a 100% valuation
allowance. The valuation allowance for the remaining net deferred tax assets was $ 2,572,885 and $ 2,343,000 as of December 31, 2022, and
2021, respectively.

 F- 13

 NOTE
6 – COMMITMENTS AND CONTINGENCIES

 From
time to time, the Company may be involved in litigation in the ordinary course of business. The Company is not currently involved in
any litigation that we believe could have a material adverse effect on its financial condition or results of operations.

 Subscription
Agreement and Cash Held in Escrow

 On
February 20, 2019, the Company entered into a subscription escrow agreement (the "Trust Agreement") with Branch Banking and
Trust Company ("BB&T"). This Trust Agreement was established for the subscription agreement proceeds raised and escrowed
pursuant to the Company's prior Rule 419 S-1 offering. The balance held in trust at September 30, 2022 and December 31, 2021, totaled
$ 19,705.

 Upon
completion of the Merger (see Notes 1 and 8), the Company issued 975,000 common stock shares to the investors in that prior S-1 offering
during July 2022 and were released to the Company.

 Consulting
Agreements

the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company paid the CEO $ 103,605 and $ 39,966, respectively,
pursuant to a consulting agreement carried over from related party NBFL. The agreement provides for an annual salary of $ 150,000 which
increases based on certain capital raise thresholds. At September 30, 2022 and December 31, 2021, accrued payroll owed to the CEO totaled
$ 188,484 and $ 186,034, respectively, as presented in the accompanying consolidated balance sheets.

 On
July 24, 2020, the Company entered into a consulting agreement for business development activities, networking, negotiations, and strategic
planning. The compensation pursuant to the agreement was $ 20,000 monthly. During the nine months ended September 30, 2022, and the year
ended December 31, 2021, $ 144,975 and $ 47,500, respectively, was paid to the consultant. Additionally, during the year ended December
31, 2021, the Company issued 500,000 shares of common stock to the consultant, valued at $ 250,000. During the nine months ended September
30, 2022, the Company issued 751,500 shares of common stock, valued at $ 325,750, to settle the amounts owed to the consultant (Note 4).
Accordingly, at September 30, 2022 and December 31, 2021, $ 0 and $ 202,500, respectively, accrued payroll remained outstanding which is
presented in the accompanying consolidated balance sheets.

 On
January 14, 2021, the Company entered into two consulting agreements for strategic advisory services to be provided through December
31, 2021. The compensation per the two agreements provided for the issuance of 1,700,000 and 450,000 shares of common stock. The stock
compensation to these two advisors totaled $ 1,073,388.

 Office
Lease

 The
Company entered into a sublease agreement with the above consultant (providing business development assistance from 2019-2020) effective
August 1, 2019, subject to the terms and conditions of the office lease held by the consultant at 15540 Quorum Drive #2624, Addison,
Texas. On January 1, 2019, the Company adopted ASC 842 requiring this lease to be recorded as an asset and corresponding liability on
its balance sheet. The Company records rent expense associated with this lease on the straight-line basis in conjunction with the terms
of the underlying lease. A discount rate was not used in the determination of the right of use asset and liability since its effect would
not be significant. The lease moved to a month-to-month basis beginning in September 2021 at $ 2,810 per month in addition to common area
maintenance charges. During the nine months ended September 30, 2022, and the year ended December 31, 2021, we incurred $ 30,240 and $ 20,094,
respectively, in office rental expense.

 Research
and Development Agreement

September 2020, the Company assumed a Cooperative Research And Development Agreement (CRADA) with the United States Department of Agriculture
(USDA), Agricultural Research Service (ARS). Under this agreement, the Company committed to funding the remaining amount due. As of September
30, 2022, and December 31, 2021, $ 246,400 and $ 243,400, respectively, remained outstanding and is presented in the accompanying consolidated
balance sheets as USDA CRADA liability.

 F- 14

 NOTE
7 – RELATED PARTY TRANSACTIONS

 Share
Issuances to the Board of Directors

December 2020, the Board of Directors allocated 11,137,833 shares of common stock among the three founders. These issuances were valued
at $.50 per share based on a third-party sale of common stock (see Note 4), totaling $ 5,560,567.

 On
March 8, 2022, the Company issued 2,000,000 shares of common stock to each of its three directors, for a total of 6,000,000 shares issued
valued at $ 3,000,000 (based on the latest third-party sale of common stock). The issuances are recorded in stock compensation in the
accompanying consolidated statement of operations.

 The
Company issued Series B preferred stock on August 16, 2022, as follows: Bradley White (Chief Executive Officer), 3 shares; Dr. Clayton
Yates (Chief Scientific Officer and Chairman), 3 shares; and Dr. Jesse Jaynes (Chief Research Officer and Director), 3 shares. See Note
4.

 Services
from Related Parties

 The
daughter of the CEO and Board member was paid $ 21,900 and $ 16,925, respectively, for clerical services provided during the nine months
ended September 30, 2022 and the year ended December 31, 2021.

 Advance
payable from CEO and Director

the year ended December 31, 2019, the Company's CEO advanced $ 5,000 to the Company. During the year ended December 31, 2021, the
CEO was advanced $ 991 and was repaid the full amount by December 31, 2021. The advance was non-interest bearing and due upon demand.

 Receivables
from Related Parties

the year ended December 31, 2020, one of the Company's directors advanced the Company $ 3,000. Later that year, $ 5,000 was repaid
leaving a total $ 2,000 receivable from the director at September 30, 2022 and 2021, respectively.

2018, Robert Bubeck, former CEO, paid $ 3,846 of expenses on behalf of the Company. The amount due to related party at both September
30, 2022 and 2021 is $ 3,846 and is due on demand and non-interest bearing.

the nine months ended September 30, 2021, Robert Bubeck, former CEO, paid $ 13,500 of accrued expenses on behalf of the Company. Since
the amount due to the shareholder is not expected to be repaid, it has been accounted for as additional paid-in capital in the accompanying
consolidated financial statements.

January 2021, in connection with the acquisition (see Note 8), Robert Bubeck resigned as CEO and Bradley White was appointed to serve
as CEO.

 F- 15

 NOTE
8 – MERGER WITH OLD GENVOR

 On
May 27, 2022, the Company, formerly known as Allure Worldwide, Inc., Merger Sub, and Old Genvor completed the Acquisition and Merger
transaction (Note 1). The transaction was completed pursuant to the Merger Agreement, pursuant to which Merger Sub merged with and into
Old Genvor, with Old Genvor continuing as a wholly owned subsidiary of the Company and the surviving corporation in the Merger. Immediately
upon completion of the Merger, the former stockholders of Old Genvor stockholders held a majority of the common stock and voting interest
of the combined company.

 In
the Merger, the Company issued shares of its common stock to Old Genvor stockholders at an exchange ratio of 1:1 (with each share of
Old Genvor common stock automatically converted in the merger into the right to receive a share of Company common stock, and a total
of 35,261,871 shares of Company common stock issued to Old Genvor's pre-merger stockholders). Pursuant to the original Acquisition
agreement and Merger, the Company's founding shareholders retained 5 % of the Company's outstanding shares of common stock,
or 1,855,888 shares (Note 4). After closing the Acquisition and for a period of two years following commencement of trading of the Company's
common stock, the Company and Old Genvor agreed that the Company will make additional issuances of the Company's common stock to
the founding shareholders to ensure that in the aggregate they maintain their 5 % ownership of the Company's outstanding common
stock.

 Pursuant
to business combination accounting for reverse acquisitions, the Company accounted for the Merger as a capital transaction (reverse recapitalization)
rather than a business combination (or asset acquisition). Since the Company was formerly a special purpose acquisition company (SPAC)
with no assets and only expenses related to maintaining its public shell company status, and Old Genvor has cash, other assets, a contract
with the USDA (Note 6), and has raised funds from investors, Old Genvor was determined to be the accounting acquirer. Because a reverse
recapitalization is equivalent to the issuance of shares by the private operating company for the net monetary assets of the public shell
company, the transaction costs incurred by Old Genvor to effect the recapitalization were recognized as a reduction in additional paid-in
capital rather than expensed as incurred. The assets and liabilities of Old Genvor were consolidated with the Company at their book value,
the equity accounts were retroactively adjusted to reflect the equity of the Company, with a balancing adjustment through the additional
paid-in capital account.

the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company paid $ 140,000 and $ 10,000, respectively,
in anticipation of closing the Acquisition. The total $ 150,000 was recognized in additional paid-in capital as of the date of the Merger.

 NOTE
9 – INTELLECTUAL PROPERTIES

 The
Company was granted a patent (#11083775) on August 10, 2021 by the United States Patent and Trademark Office. The patent was assigned
by the inventors to the Company and The United States of America, as represented by the Secretary of Agriculture.

 NOTE
10 – SUBSEQUENT EVENTS

 The
Company has evaluated subsequent events from the balance sheet through the date of this filing and determined there were no events to
disclose except the following.

 On
October 19, 2022, the Company filed a Certificate of Designation with the State of Nevada to designate its Series B. The designation
authorized 2,500,000 shares of Series B. Each share of Series B shall have 10 votes on all matters submitted to a vote of the stockholders
of the Company. Each share of Series B is convertible into 10 shares of common stock of the Company. See Note 4.

 On
October 19, 2022, the following shareholders converted shares of common stock of the Company into shares of Series B, as follows:

OF CONVERTED SHARES OF COMMON STOCK

 Name

 Common
 Shares Exchanged

 Series
 B
 Issued

 Jaynes Investment
 LLC

 2,000,000

 200,000

 ACT Holdings LLC

 7,312,612

 731,262

 LASB Family Trust

 3,800,112

 380,012

 Jesse Michael Jaynes

 4,767,611

 476,762

 Bradley White

 1,225,000

 122,500

 PJ
 Advisory Group

 1,500,000

 Total

 20,605,334

 2,060,536

 F- 16

 Item
9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure

 We
have had no disagreements with our accountants required to be disclosed pursuant to Item 304 of Regulation S-K.

 Item
9A. Controls and Procedures

 Evaluation
of Disclosure Controls and Procedures

 The
Company's Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of the Company's disclosure
controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the nine months ended September 30,
2022. Based upon such evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such
period, the Company's disclosure controls and procedures were not effective as required under Rules 13a-15(e) and 15d-15(e) under
the Exchange Act.

 Management's
Annual Report on Internal Control over Financial Reporting

 The
management of the Company is responsible for the preparation of the financial statements and related financial information appearing
in this Annual Report on Form 10-K. The financial statements and notes have been prepared in conformity with accounting principles generally
accepted in the United States of America. The management of the Company is also responsible for establishing and maintaining adequate
internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. A company's internal
control over financial reporting is defined as a process designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
Our internal control over financial reporting includes those policies and procedures that:

 Pertain
 to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets
 of the Company;

 Provide
 reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
 generally accepted accounting principles, and that receipts and expenditures of the issuer are being made only in accordance with
 authorizations of management and the board of directors of the Company; and

 Provide
 reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's
 assets that could have a material effect on the financial statements.

 Management,
including the Chief Executive Officer and Chief Financial officer, does not expect that the Company's disclosure controls and internal
controls will prevent all error and all fraud. Because of its inherent limitations, a system of internal control over financial reporting
can provide only reasonable, not absolute, assurance that the objectives of the control system are met and may not prevent or detect
misstatements. Further, over time, control may become inadequate because of changes in conditions or the degree of compliance with the
policies or procedures may deteriorate.

 With
the participation of the Chief Executive Officer and Chief Financial Officer, our management evaluated the effectiveness of the Company's
internal control over financial reporting as of September 30, 2021, based upon the framework in Internal Control –Integrated Framework
issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013. Based on that evaluation, our management
has concluded that, as of September 30, 2022, the Company had material weaknesses in its internal control over financial reporting and
the Company's internal control over financial reporting were not effective. Specifically, management identified the following material
weaknesses at September 30, 2022:

 1.

 Lack
 of oversight by independent directors in the establishment and monitoring of required internal controls and procedures;

 2.

 Lack
 of functioning audit committee, resulting in ineffective oversight in the establishment and monitoring of required internal controls
 and procedures;

 3.

 Insufficient
 personnel resources within the accounting function to segregate the duties over financial transaction processing and reporting and
 to allow for proper monitoring controls over accounting;

 4.

 Insufficient
 written policies and procedures over accounting transaction processing and period end financial disclosure and reporting processes.

 5.

 Insufficient
 process related to the closing our financial records including appropriate review of ending balances.

 To
remediate our internal control weaknesses, management intends to implement the following measures:

 The
 Company will add sufficient number of independent directors to the board and appoint an audit committee.

 The
 Company will add sufficient knowledgeable accounting personnel to properly segregate duties and to effect a timely, accurate preparation
 of the financial statements.

 Upon
 the hiring of additional accounting personnel, the Company will develop and maintain adequate written accounting policies and procedures.

 The
additional hiring is contingent upon the Company's efforts to obtain additional funding through equity or debt for its continued
operational activities and corporate expenses. Management provides no assurances that it will be able to do so.

 We
understand that remediation of material weaknesses and deficiencies in internal controls are a continuing work in progress due to the
issuance of new standards and promulgations. However, remediation of any known deficiency is among our highest priorities. Our management
will periodically assess the progress and sufficiency of our ongoing initiatives and make adjustments as and when necessary.

 As
a smaller reporting company, we are not required to provide, and this annual report does not include, an attestation report of our registered
public accounting firm regarding internal control over financial reporting.

 Changes
in Internal Control over Financial Reporting

 Except
as set forth above, there were no changes in our internal control over financial reporting that occurred during the period covered by
this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 Limitations
on the Effectiveness of Controls

 The
Company's management, including the CEO and CFO, does not expect that our disclosure controls and procedures or our internal control
over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated,
can provide only reasonable, not absolute, assurance that the control system's objectives will be met. Further, the design of the
control system must reflect that there are resource constraints and that the benefits must be considered relative to their costs. Because
of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues
and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments
in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented
by the individual acts of some persons, by collusion of two or more people, or by management override of controls. The design of any
system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that
any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls
effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration
in the degree of compliance with policies or procedures.

 Item
9B. Other Information.

 None.

 PART
III

 Item
10. Directors, Executive Officers and Corporate Governance.

 The
following table sets forth information with respect to persons who are serving as directors and officers of the Company. Each director
holds office until the next annual meeting of shareholders or until his successor has been elected and qualified.

 Name

 Age

 Position

 Bradley White

 Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer, Director (1)

 Clayton Yates

 Chief Scientific Officer, Director (1)

 Jesse Jaynes

 Chief Research Officer, Director (1)

 (1)

 Appointed on January 12, 2021.

 Biographies
of Directors and Officers

 The
following is a brief account of the education and business experience during at least the past five years of each director, executive
officer and key employee of our company, indicating the person's principal occupation during that period, and the name and principal
business of the organization in which such occupation and employment were carried out.

 Bradley
White brings over 28 years of experience in the field of business development with a passion for moving business concepts and technology
to commercial application. Mr. White has extensive expertise in seed business start-up and growth, strategic planning, and research management.
He is a proven driver of company revenue and in negotiating game changing deals with major institutions globally. Mr. White has traveled
to and transacted business on every continent, and he has a deep understanding of the business processes and cultural etiquette within
and across key countries. Prior to joining Genvor in 2018, Mr. White was a founding Partner of Alpha Financial Technologies (AFT) where
he co-created the world's first publicly traded suite of commodity indexes. While acting as Global Head of Business Development
during his 13-year tenure with AFT, his company reached peak index assets (AUM) of over $13 billion. Mr. White holds his Bachelor of
Business Administration from The University of Texas and Master of Arts, Legal Studies from Arizona State University.

 Dr.
Clayton Yates, Ph. D., co-founded Genvor and is Chairman of the Board of Genvor. His research is currently funded by the National Cancer
Institute (NCI) and Department of Defense (DOD) Congressionally Medical Directed Research Programs. Dr. Yates is also scientist at Tuskegee
University, focused on identifying molecular targets for therapeutic intervention in prostate, breast, and pancreatic cancers. Dr. Yates
received his initial training at the University of Pittsburgh School of Medicine in the Department of Cellular and Molecular Pathology.
He completed additional training in Tissue Engineering and Regenerative Medicine jointly from the McGowan Institute for Regenerative
Medicine and Massachusetts Institute of Technology (MIT). Dr. Yates completed his post-doctoral training at Emory University School of
Medicine in the Department of Molecular Urology.

 Dr.
Jesse Jaynes, Ph. D., co-founded Genvor as well, and he leads the research for Genvor and manages ongoing, critical communication with
our outside research and development partners and associations. Dr. Jaynes is one of the world's leading authorities on therapeutic
peptide design and has vast experience in drug development for various applications, including agriculture, animal health, wound healing,
and oncology. Dr. Jaynes' research is funded by USDA, NSF, and NIH. He has more than 60 United States and foreign patents and has
authored over 100 scientific journal articles. Over the past 15 years, Dr. Jaynes has served on the board of numerous life science companies
and is currently the Chief Technology Officer for the National Cancer Coalition. Dr. Jaynes is a Professor of Biochemistry at Tuskegee
University. Dr. Jaynes completed his doctoral training at Brigham Young University, Utah.

 There
are no family relationships among any of our directors and executive officers.

 Our
directors are elected at the annual meeting of the shareholders, with vacancies filled by the Board of Directors, and serve until their
successors are elected and qualified, or their earlier resignation or removal. Officers are appointed by the board of directors and serve
at the discretion of the board of directors or until their earlier resignation or removal. Any action required can be taken at any annual
or special meeting of stockholders of the corporation which may be taken without a meeting, without prior notice and without a vote,
if consent of consents in writing setting forth the action so taken, shall be signed by the holders of the outstanding stock having not
less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled
to vote thereon were present and voted and shall be delivered to the corporation by delivery to its registered office, its principle
place of business, or an officer or agent of the corporation having custody of the book in which the proceedings of meetings are recorded.

 As
we have recently devoted efforts to exploring the intersection of technology and wholistic technology-based health treatments for a variety
of mental health conditions, from autism to dementia and Alzheimer's, we have also retained Board of Advisors composed of advisors
we believe are competent to advise us regarding technology, sports health issues and treatments, and PTSD.

 Indemnification
of Directors and Officers

 Section
78.138 of the Nevada Revised Statutes ("NRS") provides that a director or officer will not be individually liable unless
it is proven that (i) the director's or officer's acts or omissions constituted a breach of his or her fiduciary duties,
and (ii) such breach involved intentional misconduct, fraud or a knowing violation of the law. Section 78.7502 of NRS permits a company
to indemnify its directors and officers against expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred
in connection with a threatened, pending or completed action, suit or proceeding if the officer or director (i) is not liable pursuant
to NRS 78.138 or (ii) acted in good faith and in a manner the officer or director reasonably believed to be in or not opposed to the
best interests of the corporation and, if a criminal action or proceeding, had no reasonable cause to believe the conduct of the officer
or director was unlawful. Section 78.751 of NRS permits a Nevada company to indemnify its officers and directors against expenses incurred
by them in defending a civil or criminal action, suit or proceeding as they are incurred and in advance of final disposition thereof,
upon receipt of an undertaking by or on behalf of the officer or director to repay the amount if it is ultimately determined by a court
of competent jurisdiction that such officer or director is not entitled to be indemnified by the company. Section 78.751 of NRS further
permits the company to grant its directors and officers additional rights of indemnification under its articles of incorporation or bylaws
or otherwise. Section 78.752 of NRS provides that a Nevada company may purchase and maintain insurance or make other financial arrangements
on behalf of any person who is or was a director, officer, employee or agent of the company, or is or was serving at the request of the
company as a director, officer, employee or agent of another company, partnership, joint venture, trust or other enterprise, for any
liability asserted against him and liability and expenses incurred by him in his capacity as a director, officer, employee or agent,
or arising out of his status as such, whether or not the company has the authority to indemnify him against such liability and expenses.

 Our
Articles of Incorporation provide that no director or officer of the Company will be personally liable to the Company or any of its stockholders
for damages for breach of fiduciary duty as a director or officer; provided, however, that the foregoing provision shall not eliminate
or limit the liability of a director or officer (i) for acts or omissions which involve intentional misconduct, fraud or knowing violation
of law, or (ii) the payment of dividends in violation of Section 78.300 of NRS. In addition, our Bylaws implement the indemnification
and insurance provisions permitted by Chapter 78 of the NRS by providing that the Company shall indemnify its directors to the fullest
extent permitted by the NRS and may, if and to the extent authorized by the board of directors, so indemnify its officers and any other
person whom it has the power to indemnify against liability, reasonable expense or other matter whatsoever; and the Company may at the
discretion of the board of directors purchase and maintain insurance on behalf of any person who holds or who has held any position identified
in the paragraph above against any and all liability incurred by such person in any such position or arising out of his status as such.

 Insofar
as indemnification by us for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling
the company pursuant to provisions of our articles of incorporation and bylaws, or otherwise, we have been advised that in the opinion
of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. In the event
that a claim for indemnification by such director, officer or controlling person of us in the successful defense of any action, suit
or proceeding is asserted by such director, officer or controlling person in connection with the securities being offered, we will, unless
in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue.

 Director
Compensation

the nine months ended September 30, 2022 and the year ended December 31, 2021, we did not have an independent director. Directors that
were employees were not paid any fees for their role as director.

 Involvement
on Certain Material Legal Proceedings During the Last Five Years

 No
director, officer, significant employee or consultant has been convicted in a criminal proceeding, exclusive of traffic violations.

 No
bankruptcy petitions have been filed by or against any business or property of any director, officer, significant employee or consultant
of the Company nor has any bankruptcy petition been filed against a partnership or business association where these persons were general
partners or executive officers.

 No
director, officer, significant employee or consultant has been permanently or temporarily enjoined, barred, suspended or otherwise limited
from involvement in any type of business, securities or banking activities.

 No
director, officer or significant employee has been convicted of violating a federal or state securities or commodities law.

 Directors'
and Officers' Liability Insurance

 The
Company does not have directors' and officers' liability insurance insuring our directors and officers against liability
for acts or omissions in their capacities as directors or officers.

 Code
of Ethics

 We
intend to adopt a code of ethics that applies to our officers, directors and employees, including our principal executive officer and
principal accounting officer, but have not done so to date due to our relatively small size. We intend to adopt a written code of ethics
in the near future.

 Corporate
Governance and Board Independence

 Our
Board of Directors consists of three directors and has not established a Nominating or Governance Committees as standing committees.
The Board does not have an executive committee or any committees performing a similar function. We are not currently listed on a national
securities exchange or in an inter-dealer quotation system that has requirements that a majority of the board of directors be independent.

 Due
to our lack of operations and size, and since we are not currently listed on a national securities exchange, we are not subject to any
listing requirements mandating the establishment of any particular committees; all functions of a nominating/governance committee were
performed by our whole board of directors. Our board of directors intends to appoint such persons and form such committees as are required
to meet the corporate governance requirements imposed by the national securities exchanges as necessary. Our board of directors does
not believe that it is necessary to have such committees at the early stage of the company's development, and our board of directors
believes that the functions of such committees can be adequately performed by the members of our board of directors.

 We
believe that our board of directors is capable of analyzing and evaluating our financial statements and understanding internal controls
and procedures for financial reporting. We believe that retaining an independent director who would qualify as an "audit committee
financial expert" would be overly costly and burdensome and is not warranted in our circumstances given the early stages of our
development and the fact that we have not generated any material revenues to date.

 Board
Leadership Structure and the Board's Role in Risk Oversight.

 The
Board of Directors is led by a Chairman and at this time, our Chairman is also our Chief Executive Officer. Although our sole officer
is our sole director, the Board believes that the most effective leadership structure at this time is not to separate the roles of Chairman
and Chief Executive Officer. A combined structure provides the Company with a single leader who represents the company to our stockholders,
regulators, business partners and other stakeholders, among other reasons set forth below.

 This
 structure creates efficiency in the preparation of the meeting agendas and related Board materials as the Company's Chief Executive
 Officer works directly with those individuals preparing the necessary Board materials and is more connected to the overall daily
 operations of the Company. Agendas are also prepared with the permitted input of the full Board of Directors allowing for any concerns
 or risks of any individual director to be discussed as deemed appropriate. The Board believes that the Company has benefited from
 this structure, and Mr. Perry's continuation in the combined role of the Chairman and Chief Executive Officer is in the best
 interest of the stockholders.

 The
 Company believes that the combined structure is necessary and allows for efficient and effective oversight, given the Company's
 relatively small size, its corporate strategy and focus.

 The
Board of Directors does not have a specific role in risk oversight of the Company. The Chairman, President and Chief Executive Officer
and other executive officers and employees of the Company provide the Board of Directors with information regarding the Company's
risks.

 Item
11. Executive Compensation

 The
table below sets forth, for our last two fiscal years ending September 30, 2022 ("2022") and December 31, 2021 ("2021"),
the compensation earned by our executive officers and former executive officers.

 Option

 All

 Deferred

 and

 Other

 Name and

 Compen-

 Stock

 Warrant

 Compen-

 Principal Position

 Salary

 sation

 Bonus

 Awards

 Awards

 sation

 Total

 Bradley White

 2022

 $
 112,500

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 112,500

 Chief Executive Officer, Chief Financial Officer, and Director (1)

 2021

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 Dr. Clayton Yates

 2022

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 Chief Scientific Officer, Director (1)

 2021

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 Dr. Jesse Jaynes

 2022

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 Chief Research Officer, Director (1)

 2021

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 Robert Bubeck

 2022

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 Former Chief Executive Officer, Former Chief Financial Officer, Former Director (2)

 2021

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 Margaret McLaughlin

 2022

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 Former Secretary, Former Director (2)

 2021

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 (1)

 Appointed
 on January 12, 2021.

 (2)

 Resigned
 on January 12, 2021.

 There
are no current employment agreements between the Company and its officers and directors, and no compensation was earned by or paid to
our officers and directors during the fiscal years ending September 30, 2022 and December 31, 2021.

 No
retirement, pension, profit sharing, stock option or insurance programs or other similar programs have been adopted by us for the benefit
of our officer or director or employees.

 Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 The
following table sets forth certain information regarding beneficial ownership of our common stock as of March 17, 2023, by (i) each person
known by us to be the beneficial owner of more than 5% of any class of our voting equity, (ii) each director and each of our named executive
officers and (iii) all executive officers and directors as a group.

 The
number of shares of stock beneficially owned by each person is determined under the rules of the SEC and the information is not necessarily
indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares as to which such
person has sole or shared voting power or investment power and also any shares which the individual has the right to acquire within 60
days after the date hereof, through the exercise of any stock option, warrant or other right. Unless otherwise indicated, each person
has sole investment and voting power (or shares such power with his or her spouse) with respect to the shares set forth in the following
table. The inclusion herein of any shares deemed beneficially owned does not constitute an admission of beneficial ownership of those
shares.

 The
information reflected in the following table was, unless otherwise specified, the address of each of the persons set forth below, or
is in care of the Company at the Company's address.

 Title of Class

 Name & Address of Beneficial Owners

 Amount & Nature

 of Beneficial Ownership (1)

 Percent of

 Class (2)

 Bradley White (3)

 5,025,120 (4
)

 21.7
 %

 Dr. Clayton Yates (5)

 7,312,620 (6
)

 27.2
 %

 Dr. Jesse Jaynes (7)

 6,767,620 (8
)

 21.7
 %

 All Officers and Directors as a Group

 19,105,360

 51.3
 %

 John Coutris

 1,500,000 (9
)

 7.6
 %

 Judy Miller

 1,106,170 (10
)

 6.1
 %

 All Officers and Directors as a Group

 71,938,459

 62.67
 %

 Bradley White

 502,512

 24.4
 %

 Dr. Clayton Yates

 731,262

 35.5
 %

 Dr. Jesse Jaynes

 676,762

 32.8
 %

 All Officers and Directors as a Group

 1,910,536

 92.7
 %

 John Coutris

 7.3
 %

 (1)

 Beneficial
 ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment
 power with respect to securities. Each of the beneficial owners listed above has direct ownership of and sole voting power and investment
 power with respect to the shares of the Company's common stock unless otherwise stated herein.

 (2)

 As
 of March 24, 2023, a total of 18,122,821 shares of the Company's common stock, and 2,060,536 shares of Series B Preferred Stock
 are considered to be outstanding pursuant to SEC Rule 13d-3(d)(1). For each beneficial owner above, any shares of common stock issuable
 upon conversion of Series B Preferred Stock within 60 days have been included for purposes of calculating the relevant percentage
 ownership. Each share of Series B Preferred Stock converts into 10 shares of common stock at the election of the holder.

 (3)

 Chief
 Executive Officer & Director.

 (4)

 122,500
 shares of Series B Preferred Stock are held in the name of Mr. White, 380,012 shares of Series B Preferred Stock are held in the
 name of the LASB Family Trust, which may be deemed to be beneficially owned by Mr. White, and such shares of preferred stock are
 convertible into 5,025,120 shares of common stock.

 (5)

 Chief
 Science Officer & Director.

 (6)

 731,262
 shares of Series B Preferred Stock are held in the name of ACT Holdings LLC, which may be deemed to be beneficially owned by Dr.
 Yates, and such shares of preferred stock are convertible into 7,312,620 shares of common stock.

 (7)

 Chief
 Research Officer & Director.

 (8)

 476,762
 shares of Series B Preferred Stock are held jointly in the name of Dr. Jaynes and his spouse, 200,000 shares of Series B Preferred
 Stock held in the name of the Jaynes Investment LLC, which may be deemed to be beneficially owned by Dr. Jaynes, and such shares
 of preferred stock are convertible into 6,767,620 shares of common stock.

 (9)

 shares of Series B Preferred Stock are held in the name of PJ Advisory Group, which may be deemed to be beneficially owned by Mr.
 Coutris, and such shares of preferred stock are convertible into 1,500,000 shares of common stock. Upon belief, the address of PJ
 Advisory Group is 7227 Centenery Ave., Dallas, Texas, 75225.

 (10)

 1,106,170
 shares of Common Stock are held in the name of Good Works Funding Inc., which may be deemed to be beneficially owned by Ms. Miller.
 Upon belief, the address of Good Works Funding Inc. is 201 S. Elliott Rd., #550, Chapel Hill, North Carolina, 27514.

 Item
13. Certain Relationships and Related Transactions

 Transactions
with Related Persons

 None

 The
Company does not own or rent property. The office space is provided by an officer at no charge.

 Director
Independence

 We
currently do not have any independent directors, as the term "independent" is defined in Section 803A of the NYSE American
Company Guide. The Board has made its determination as to director independence based on the definition of "independence"
as defined under the rules of the New York Stock Exchange ("NYSE") and NYSE American.

 Item
14. Principal Accounting Fees and Services.

 The
following table sets forth the fees billed by our principal independent accountants for the years ended September 30, 2022 and 2021,
for the categories of services indicated.

 Category

 Nine
 Months

 Ended
 September 30, 2022

 Year
 Ended
 December 31, 2021

 Audit fees

 $
 42,000

 $
 20,000

 Audit related fees

 -

 -

 Tax fees

 -

 -

 All other fees

 -

 -

 Total

 $
 42,000

 $
 20,000

 On
December 16, 2020, we notified Adeptus Partners LLC ("Adeptus") of their dismissal as our independent registered public accounting
firm. On December 16, 2020, we engaged Turner, Stone & Company, L.L.P. ("Turner") of Dallas, Texas, as our new independent
registered public accounting firm.

 Audit
fees. Consists of fees billed for the audit of our annual financial statements and review of our interim financial information and
services that are normally provided by the accountant in connection with year-end and quarter-end statutory and regulatory filings or
engagements.

 Audit-related
fees. Consists of fees billed for services relating to review of other regulatory filings including registration statements, periodic
reports and audit related consulting.

 Tax
fees. Consists of professional services rendered by our principal accountant for tax compliance, tax advice and tax planning.

 Other
fees. Other services provided by our accountants.

 Item
15. Exhibits, Financial Statement Schedules

 Exhibit

 Description

 3.1

 Florida Articles of Incorporation (incorporated by reference to Exhibit 3.A to our Registration Statement on Form S-1, filed on May 4, 2020)

 3.2

 Nevada Articles of Incorporation (incorporated by reference to Exhibit 3.2 to our Quarterly Report on Form 10-Q, filed on July 20, 2021)

 3.3

 Certificate of Correction to Nevada Articles of Incorporation (incorporated by reference to Exhibit 3.3 to our Quarterly Report on Form 10-Q, filed on July 20, 2021)

 3.4

 Bylaws (incorporated by reference to Exhibit 3.B to our Registration Statement on Form S-1, filed on May 4, 2020)

 10.1*

 Exchange Agreement, by and between the Company and Genvor Inc. (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on February 1, 2021)

 10.2*

 Agreement and Plan of Merger, by and between the Company, Genvor Inc., and Genvor Acquisition Corp. (incorporated by reference to Exhibit 10.2 to our Annual Report on Form 10-K filed on March 21, 2022)

 31.1**

 Certification of CEO required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 31.2**

 Certification of CFO required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 32.1**

 Certification of CEO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 of 18 U.S.C. 63

 32.2**

 Certification of CFO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 of 18 U.S.C. 63

 101.INS***

 101.SCH***

 101.CAL***

 101.DEF***

 101.LAB***

 101.PRE***

 Cover

 *
Certain schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule or exhibit
will be furnished supplementally to the Securities and Exchange Commission upon request; provided, however that the Company may request
confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedule or Exhibit so furnished.

 **
Filed herewith.

 ***
for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

 SIGNATURES

 Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.

 /s/
 Judith S. Miller

 January
 16, 2024

 Interim
 Chief Executive Officer and

 Date

 Interim
 Chief Financial Officer

 Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.

 /s/
 Dr. Jesse Jaynes

 January
 16, 2024

 Director

 Date

 /s/
 Dr. Clayton Yates

 January
 16, 2024

 Director

 Date